Skip to content

Tissue Repair & Anti-Inflammatory

Pentosan Polysulfate Sodium (PPS)

FDA-approved oral IC drug (Elmiron) also used off-label by injection for osteoarthritis; long-term oral use can harm the retina.

FDA approvedEvidence level 5 of 5: FDA-approved / large RCTsAlso: Elmiron, PPS, Zilosul (investigational injectable), Cartrophen (veterinary)

Overview

Pentosan polysulfate sodium is a semi-synthetic, heparin-like polysaccharide made from beech-tree hemicellulose. It is not a peptide. Taken orally as Elmiron, it is thought to coat and help restore the protective glycosaminoglycan layer of the bladder lining, and it is FDA-approved for the pain of interstitial cystitis, with benefits emerging over three to six months. By injection it has anti-inflammatory and cartilage-protective effects, inhibiting cartilage-degrading enzymes and improving joint circulation; it is widely used in veterinary osteoarthritis and is being tested in human knee osteoarthritis. It has mild blood-thinning effects. Importantly, long-term oral use has been linked to a distinctive pigmentary maculopathy of the retina, so regular eye examinations are required.

Classification
Semi-synthetic polysulfated polysaccharide (heparin-like; not a peptide)
Route
Oral (approved); subcutaneous or intra-articular (off-label/investigational)
Half-life
~4.8 hours (oral, Elmiron label)

Mechanism of action

Primary targetBladder glycosaminoglycan layer; cartilage-degrading enzymes and inflammatory mediators
  1. Oral or injected dosingOral form concentrates in urine; injection reaches joint tissues.
  2. GAG layer reinforcementAdheres to bladder mucosa, reducing irritant penetration.
  3. Mast cell and cytokine dampingReduces histamine release and inflammatory signaling.
  4. Cartilage enzyme inhibitionInhibits ADAMTS and MMP enzymes that break down cartilage.
  5. Improved subchondral circulationFibrinolytic and lipid-mobilizing effects improve joint microcirculation.
Downstream effects
  • Reduced IC bladder pain
  • Improved joint comfort
  • Mild anticoagulation

Researched for

  • Interstitial cystitis / bladder pain syndrome
  • Knee osteoarthritis
  • Mucopolysaccharidosis (investigational)
  • Bone marrow edema

Research notes

  • Placebo-controlled trials supported FDA approval; roughly a third of patients report meaningful IC symptom improvement.
  • Pearce et al. (2018) identified pigmentary maculopathy with chronic Elmiron use; risk rises with cumulative dose.
  • Small human trials of subcutaneous PPS in knee OA show pain and function improvements; Phase 3 trials are ongoing.
  • Long used in veterinary (equine, canine) osteoarthritis.

Reported side effects

  • Pigmentary maculopathy with long-term oral use
  • Bruising or bleeding
  • Nausea, diarrhea, abdominal pain
  • Hair thinning (rare)
  • Mild liver enzyme elevation

Contraindications & cautions

  • Known hypersensitivity to PPS
  • Active bleeding or high bleeding risk (caution with anticoagulants)
  • Pre-existing macular disease
  • Planned surgery (anticoagulant effect)

Lab monitoring

  • CBC with platelets
  • CMP and liver enzymes
  • PT/INR, aPTT if on anticoagulants
  • Baseline and annual retinal exam with imaging (chronic oral use)
  • Symptom scores (IC pain diary or WOMAC)

Dosing and pricing for Pentosan Polysulfate Sodium (PPS)

Dosing references and compound pricing are available to established patients in the secure portal after a medical evaluation.

Ready to take control of your health?

Start with a 60-minute physician evaluation, virtually in seven states or in person in Reston, Virginia.

Request a consultation 703-400-5314

Cash-pay. HSA and FSA accepted. Monday–Friday, 10 AM – 2 PM (virtual and in person).